Emma Guttman-Yassky | sciencenewsnet.in

Breaking News

Study identifies hip implant materials with the lowest risk of needing revision

New study links liver-brain communication to daily eating patterns

American Joint Replacement Registry Surpasses 4 Million Captured Hip and Knee Arthroplasty Procedures

Scientists Capture Images of Electron Molecular Crystals

Does more virtual care mean more low-value care? Study suggests no

New Survey from Heterodox Academy and College Pulse of 1,500+ Canadian Undergraduates Shows Fear of Free Expression on Campus

Mayo Clinic researchers recommend alternatives to hysterectomy for uterine fibroids, according to study

New AI-based natural language feature makes complex searches in Dimensions faster and easier

Atomic-level heterostructures for enhanced photocatalytic hydrogen evolution

07 Nov, 2024

Mount Sinai Secures Over $4 Million Grant From National Institutes of Health to Study Alopecia Areata and Atopic Dermatitis in People With Down Syndrome

July 11, 2024 sarah JonasAnnouncement

First-of-its-kind clinical trial with specific JAK inhibition will investigate the best treatment for inflammatory skin conditions in these patients

Emma Guttman-Yassky, MD, PhD, Receives High Honor at European Academy of Allergy and Clinical Immunology

June 4, 2024 sarah JonasAnnouncement

The Paul Ehrlich Award for Experimental Research recognizes scientists who have revolutionized the understanding of allergic diseases and immunological mechanisms.

Oral Medication Shows Strong Promise for Moderate to Severe Atopic Dermatitis in Mount Sinai-led Study

May 20, 2021 sarah JonasResearch Results

An oral medication called upadacitinib yielded rapid and significant improvements in patients with moderate to severe atopic dermatitis (AD), also known as eczema, in phase 3 clinical trials, Mount Sinai researchers reported today in The Lancet online.